Literature DB >> 19146388

Evidence that alpha-synuclein does not inhibit phospholipase D.

Irit Rappley1, Aaron D Gitler, Paige E Selvy, Matthew J LaVoie, Bruce D Levy, H Alex Brown, Susan Lindquist, Dennis J Selkoe.   

Abstract

pan class="Gene">Alpha-synuclein (n>n class="Gene">alphaSyn) is a small cytosolic protein of unknown function, which is highly enriched in the brain. It is genetically linked to Parkinson's disease (PD) in that missense mutations or multiplication of the gene encoding alphaSyn causes early onset familial PD. Furthermore, the neuropathological hallmarks of both sporadic and familial PD, Lewy bodies and Lewy neurites, contain insoluble aggregates of alphaSyn. Several studies have reported evidence that alphaSyn can inhibit phospholipase D (PLD), which hydrolyzes phosphatidylcholine to form phosphatidic acid and choline. Although various hypotheses exist regarding the roles of alphaSyn in health and disease, no other specific biochemical function for this protein has been reported to date. Because PLD inhibition could represent an important function of alphaSyn, we sought to extend existing reports on this interaction. Using purified proteins, we tested the ability of alphaSyn to inhibit PLD activity in cell-free assays. We also examined several cell lines and transfection conditions to assess whether alphaSyn inhibits endogenous or overexpressed PLD in cultured mammalian cells. In yeast, we extended our previous report of an interaction between alphaSyn and PLD-dependent phenotypes, for which PLD activity is absolutely necessary. Despite testing a range of experimental conditions, including those previously published, we observed no significant inhibition of PLD by alphaSyn in any of these systems. We propose that the previously reported effects of alphaSyn on PLD activity could be due to increased endoplasmic reticulum-related stress associated with alphaSyn overexpression in cells, but are not likely due to a specific and direct interaction between alphaSyn and PLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19146388      PMCID: PMC2683767          DOI: 10.1021/bi801871h

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  44 in total

1.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

2.  alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells.

Authors:  Bong-Hyun Ahn; Hyangshuk Rhim; Shi Yeon Kim; Young-Mo Sung; Mun-Yong Lee; Ju-Youn Choi; Benjamin Wolozin; Jong-Soo Chang; Young Han Lee; Taeg Kyu Kwon; Kwang Chul Chung; Shin-Hee Yoon; Sang June Hahn; Myung-Suk Kim; Yang-Hyeok Jo; Do Sik Min
Journal:  J Biol Chem       Date:  2002-01-30       Impact factor: 5.157

Review 3.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

4.  Role of the unfolded protein response pathway in regulation of INO1 and in the sec14 bypass mechanism in Saccharomyces cerevisiae.

Authors:  Hak J Chang; Elizabeth W Jones; Susan A Henry
Journal:  Genetics       Date:  2002-09       Impact factor: 4.562

5.  Yeast cells provide insight into alpha-synuclein biology and pathobiology.

Authors:  Tiago Fleming Outeiro; Susan Lindquist
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

Review 6.  Measurement of G protein-coupled receptor-stimulated phospholipase D activity in intact cells.

Authors:  Stephanie J Walker; H Alex Brown
Journal:  Methods Mol Biol       Date:  2004

7.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

Authors:  Marie-Christine Chartier-Harlin; Jennifer Kachergus; Christophe Roumier; Vincent Mouroux; Xavier Douay; Sarah Lincoln; Clotilde Levecque; Lydie Larvor; Joris Andrieux; Mary Hulihan; Nawal Waucquier; Luc Defebvre; Philippe Amouyel; Matthew Farrer; Alain Destée
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.

Authors:  P Ibáñez; A-M Bonnet; B Débarges; E Lohmann; F Tison; P Pollak; Y Agid; A Dürr; A Brice
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

9.  The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.

Authors:  Juan J Zarranz; Javier Alegre; Juan C Gómez-Esteban; Elena Lezcano; Raquel Ros; Israel Ampuero; Lídice Vidal; Janet Hoenicka; Olga Rodriguez; Begoña Atarés; Verónica Llorens; Estrella Gomez Tortosa; Teodoro del Ser; David G Muñoz; Justo G de Yebenes
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

10.  Structural determinants of PLD2 inhibition by alpha-synuclein.

Authors:  Jacqueline E Payton; Richard J Perrin; Wendy S Woods; Julia M George
Journal:  J Mol Biol       Date:  2004-04-02       Impact factor: 5.469

View more
  16 in total

Review 1.  Folding and misfolding of alpha-synuclein on membranes.

Authors:  Igor Dikiy; David Eliezer
Journal:  Biochim Biophys Acta       Date:  2011-09-16

Review 2.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

3.  The function of α-synuclein.

Authors:  Jacob T Bendor; Todd P Logan; Robert H Edwards
Journal:  Neuron       Date:  2013-09-18       Impact factor: 17.173

Review 4.  Phospholipase D in brain function and Alzheimer's disease.

Authors:  Tiago Gil Oliveira; Gilbert Di Paolo
Journal:  Biochim Biophys Acta       Date:  2010-04-23

5.  Synphilin-1 inhibits alpha-synuclein degradation by the proteasome.

Authors:  Beatriz Alvarez-Castelao; José G Castaño
Journal:  Cell Mol Life Sci       Date:  2010-11-20       Impact factor: 9.261

6.  α-Synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Frederic Nha Nguyen; Fredric P Manfredsson; Galina Kondrikova; Layla F Sullivan; Craig Meyers; Weijun Chen; Ronald J Mandel; Nicholas Muzyczka
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

Review 7.  Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.

Authors:  Ronald C Bruntz; Craig W Lindsley; H Alex Brown
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

Review 8.  Structure and regulation of human phospholipase D.

Authors:  Forrest Z Bowling; Michael A Frohman; Michael V Airola
Journal:  Adv Biol Regul       Date:  2021-01-03

Review 9.  Mammalian phospholipase D: Function, and therapeutics.

Authors:  M I McDermott; Y Wang; M J O Wakelam; V A Bankaitis
Journal:  Prog Lipid Res       Date:  2019-12-09       Impact factor: 16.195

10.  Molecular events underlying Parkinson's disease - an interwoven tapestry.

Authors:  Kah-Leong Lim; Cheng-Wu Zhang
Journal:  Front Neurol       Date:  2013-04-08       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.